Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Joint

Nasdaq:JYNT
Snowflake Description

Outstanding track record with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
JYNT
Nasdaq
$141M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • Joint has significant price volatility in the past 3 months.
JYNT Share Price and Events
7 Day Returns
-2.9%
NasdaqCM:JYNT
-4%
US Healthcare
-4.1%
US Market
1 Year Returns
-40.2%
NasdaqCM:JYNT
-4.6%
US Healthcare
-14.9%
US Market
JYNT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Joint (JYNT) -2.9% -33.6% -38.4% -40.2% 165.5% 23.4%
US Healthcare -4% -12.9% -18.2% -4.6% 12.3% 13.1%
US Market -4.1% -19.1% -23.4% -14.9% 3.5% 14.5%
1 Year Return vs Industry and Market
  • JYNT underperformed the Healthcare industry which returned -4.6% over the past year.
  • JYNT underperformed the Market in United States of America which returned -14.9% over the past year.
Price Volatility
JYNT
Industry
5yr Volatility vs Market

Value

 Is Joint undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Joint to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Joint.

NasdaqCM:JYNT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:JYNT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.66
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.656 (1 + (1- 21%) (10.11%))
0.805
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.805 * 5.44%)
6.12%

Discounted Cash Flow Calculation for NasdaqCM:JYNT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Joint is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqCM:JYNT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.12%)
2020 3.86 Analyst x2 3.63
2021 6.90 Analyst x2 6.13
2022 9.12 Analyst x1 7.63
2023 10.80 Est @ 18.36% 8.51
2024 12.24 Est @ 13.37% 9.10
2025 13.45 Est @ 9.88% 9.42
2026 14.45 Est @ 7.44% 9.54
2027 15.28 Est @ 5.73% 9.50
2028 15.97 Est @ 4.53% 9.36
2029 16.56 Est @ 3.69% 9.15
Present value of next 10 years cash flows $81.00
NasdaqCM:JYNT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $16.56 × (1 + 1.74%) ÷ (6.12% – 1.74%)
$384.91
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $384.91 ÷ (1 + 6.12%)10
$212.58
NasdaqCM:JYNT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $81.00 + $212.58
$293.58
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $293.58 / 13.88
$21.15
NasdaqCM:JYNT Discount to Share Price
Calculation Result
Value per share (USD) From above. $21.15
Current discount Discount to share price of $10.17
= -1 x ($10.17 - $21.15) / $21.15
51.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Joint is available for.
Intrinsic value
>50%
Share price is $10.17 vs Future cash flow value of $21.15
Current Discount Checks
For Joint to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Joint's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Joint's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Joint's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Joint's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:JYNT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $0.24
NasdaqCM:JYNT Share Price ** NasdaqCM (2020-04-02) in USD $10.17
United States of America Healthcare Industry PE Ratio Median Figure of 45 Publicly-Listed Healthcare Companies 20.24x
United States of America Market PE Ratio Median Figure of 2,944 Publicly-Listed Companies 12.5x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Joint.

NasdaqCM:JYNT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:JYNT Share Price ÷ EPS (both in USD)

= 10.17 ÷ 0.24

42.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Joint is overvalued based on earnings compared to the US Healthcare industry average.
  • Joint is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Joint's expected growth come at a high price?
Raw Data
NasdaqCM:JYNT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 42.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
29.4%per year
United States of America Healthcare Industry PEG Ratio Median Figure of 32 Publicly-Listed Healthcare Companies 1.52x
United States of America Market PEG Ratio Median Figure of 2,008 Publicly-Listed Companies 0.91x

*Line of best fit is calculated by linear regression .

NasdaqCM:JYNT PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 42.28x ÷ 29.4%

1.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Joint is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Joint's assets?
Raw Data
NasdaqCM:JYNT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.41
NasdaqCM:JYNT Share Price * NasdaqCM (2020-04-02) in USD $10.17
United States of America Healthcare Industry PB Ratio Median Figure of 94 Publicly-Listed Healthcare Companies 2.31x
United States of America Market PB Ratio Median Figure of 5,142 Publicly-Listed Companies 1.22x
NasdaqCM:JYNT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:JYNT Share Price ÷ Book Value per Share (both in USD)

= 10.17 ÷ 0.41

24.68x

* Primary Listing of Joint.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Joint is overvalued based on assets compared to the US Healthcare industry average.
X
Value checks
We assess Joint's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Joint has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Joint expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
29.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Joint expected to grow at an attractive rate?
  • Joint's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Joint's earnings growth is expected to exceed the United States of America market average.
  • Joint's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:JYNT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:JYNT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 29.4%
NasdaqCM:JYNT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 18.2%
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 6.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:JYNT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:JYNT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 76 11 7 1
2021-12-31 75 10 7 5
2020-12-31 60 7 4 6
2020-04-03
NasdaqCM:JYNT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 48 8 3
2019-09-30 40 8 3
2019-06-30 36 8 2
2019-03-31 34 6 1
2018-12-31 37 5 0
2018-09-30 34 3 -1
2018-06-30 31 1 -1
2018-03-31 28 1 -2
2017-12-31 25 0 -3
2017-09-30 24 -2 -9
2017-06-30 23 -4 -11
2017-03-31 22 -6 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Joint's earnings are expected to grow significantly at over 20% yearly.
  • Joint's revenue is expected to grow by 18.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:JYNT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Joint Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:JYNT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 0.46 0.46 0.46 1.00
2021-12-31 0.44 0.57 0.34 5.00
2020-12-31 0.28 0.37 0.09 6.00
2020-04-03
NasdaqCM:JYNT Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 0.24
2019-09-30 0.19
2019-06-30 0.13
2019-03-31 0.09
2018-12-31 0.01
2018-09-30 -0.04
2018-06-30 -0.05
2018-03-31 -0.13
2017-12-31 -0.26
2017-09-30 -0.69
2017-06-30 -0.86
2017-03-31 -1.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Joint is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Joint's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Joint has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Joint performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Joint's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Joint has delivered over 20% year on year earnings growth in the past 5 years.
  • Joint's 1-year earnings growth exceeds its 5-year average (2165.7% vs 39.3%)
  • Joint's earnings growth has exceeded the US Healthcare industry average in the past year (2165.7% vs 14%).
Earnings and Revenue History
Joint's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Joint Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:JYNT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 48.45 3.32 37.46
2019-09-30 39.67 2.57 30.06
2019-06-30 36.19 1.75 27.64
2019-03-31 33.82 1.24 25.81
2018-12-31 36.66 0.15 30.06
2018-09-30 33.57 -0.50 27.91
2018-06-30 30.86 -0.73 25.87
2018-03-31 28.06 -1.70 24.44
2017-12-31 24.92 -3.43 22.59
2017-09-30 23.83 -8.98 23.44
2017-06-30 22.79 -11.17 24.50
2017-03-31 21.77 -13.41 25.52
2016-12-31 20.52 -15.17 26.43
2016-09-30 18.51 -12.79 25.56
2016-06-30 17.14 -11.82 23.89
2016-03-31 15.59 -10.42 21.35
2015-12-31 13.84 -8.80 18.67
2015-09-30 12.13 -7.98 15.30
2015-06-30 9.81 -6.53 11.69
2015-03-31 8.11 -4.81 8.84
2014-12-31 7.12 -3.03 6.19
2014-09-30 6.71 -0.46 4.85
2014-06-30 6.37 -0.22 4.20
2014-03-31 6.11 -0.01 3.67
2013-12-31 5.96 0.16 3.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Joint made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • Joint used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.
  • Joint has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Joint's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Joint has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Joint's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Joint's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Joint's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Joint's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Joint's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Joint has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Joint Company Filings, last reported 3 months ago.

NasdaqCM:JYNT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 5.72 0.00 8.46
2019-09-30 3.80 1.00 7.83
2019-06-30 2.73 1.00 9.49
2019-03-31 2.07 1.00 8.09
2018-12-31 0.73 1.10 8.72
2018-09-30 1.33 1.10 5.61
2018-06-30 1.35 1.10 4.58
2018-03-31 1.06 1.10 4.03
2017-12-31 1.15 1.10 4.22
2017-09-30 4.69 1.10 2.63
2017-06-30 4.58 1.10 3.05
2017-03-31 5.49 1.17 2.68
2016-12-31 6.93 0.33 3.01
2016-09-30 12.26 0.33 3.39
2016-06-30 14.71 0.55 6.12
2016-03-31 17.35 0.46 10.37
2015-12-31 20.68 0.58 16.79
2015-09-30 10.86 0.63 9.52
2015-06-30 12.16 0.62 12.58
2015-03-31 13.86 0.26 17.08
2014-12-31 15.63 0.00 20.80
2014-09-30 -1.64 0.00 2.37
2014-06-30 -1.45 0.00 3.26
2014-03-31 -1.33 0.00 3.02
2013-12-31 -1.22 0.00 3.52
  • Joint has no debt.
  • Joint had no debt 5 years ago.
  • Joint has no debt, it does not need to be covered by operating cash flow.
  • Joint has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Joint's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Joint has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Joint's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Joint dividends.
If you bought $2,000 of Joint shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Joint's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Joint's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:JYNT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 1.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1941 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:JYNT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Joint has not reported any payouts.
  • Unable to verify if Joint's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Joint's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Joint has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Joint's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Joint afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Joint has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Joint's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Holt
COMPENSATION $724,701
AGE 60
TENURE AS CEO 3.7 years
CEO Bio

Mr. Peter D. Holt has been Chief Executive Officer of The Joint Corp. since August 11, 2016 and has been its President since January 2017. Mr. Holt served as Interim Principal Financial Officer at The Joint Corp. since August 7, 2018 until November 2018. He served as an Acting Chief Executive Officer of The Joint Corp. since June 30, 2016 until August 11, 2016 and served as its Chief Operating Officer since April 2016 until August 11, 2016. Mr. Holt served as the Chief Executive Officer and President of Planet Smoothie, LLC from December 31, 2012 to May 2016. He served as the Chief Executive Officer and President of Tasti D-Lite, LLC from January 1, 2013 to May 2016. Mr. Holt served as the Chief Operating Officer of Tasti D-Lite, LLC. He served as Chief Operating Officer of 24seven Vending (U.S), where he launched its franchise system in the U.S., and as Executive Vice President of International for Mail Boxes Etc. and Vice President of International for I Can't Believe It's Yogurt! and Java Coast Fine Coffees. He has more than 30 years of experience in domestic and international franchising, franchise development and operations. He has a sharp eye for business growth opportunities, most recently working with Great Hill Partners, a Boston-based private equity fund with more than $1.5 billion of capital under management, on the creation of a winning franchise portfolio. He has seen the franchise business from all sides, starting with the International Franchise Association, the oldest and largest trade association in the world serving the interests of businesses that franchise. He also served as Chairman of IFA International Affairs Network, IFA Global Marketing Group. He has been a Director of The Joint Corp. since August 11, 2016. Mr. Holt holds an M.A. degree from the University of London and a B.A. from the University of Washington, where he graduated cum laude.

CEO Compensation
  • Peter's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Peter's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Joint management team in years:

3.7
Average Tenure
60
Average Age
  • The tenure for the Joint management team is about average.
Management Team

Peter Holt

TITLE
CEO, President & Director
COMPENSATION
$725K
AGE
60
TENURE
3.7 yrs

Jake Singleton

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
37
TENURE
1.4 yrs

Jorge Armenteros

TITLE
Vice President of Operations
TENURE
3.3 yrs

Jason Greenwood

TITLE
Vice President of Marketing

Amy Karroum

TITLE
Vice President of Human Resources

Craig Colmar

TITLE
Secretary
COMPENSATION
$75K
AGE
66
TENURE
10.1 yrs

Steven Knauf

TITLE
Director of Chiropractic & Compliance
TENURE
4.5 yrs

Eric Simon

TITLE
Vice President of Franchise Sales & Development

David Glover

TITLE
Regional Developer for West Lake Hills

Richard Matthews

TITLE
Director of Real Estate Research
Board of Directors Tenure

Average tenure and age of the Joint board of directors in years:

2.8
Average Tenure
60
Average Age
  • The average tenure for the Joint board of directors is less than 3 years, this suggests a new board.
Board of Directors

Ron DaVella

TITLE
Independent Director
COMPENSATION
$89K
AGE
62
TENURE
5.4 yrs

Peter Holt

TITLE
CEO, President & Director
COMPENSATION
$725K
AGE
60
TENURE
3.7 yrs

Jim Amos

TITLE
Independent Director
COMPENSATION
$85K
AGE
73
TENURE
4.6 yrs

Matt Rubel

TITLE
Lead Director
COMPENSATION
$90K
AGE
61
TENURE
2.7 yrs

Suzanne Decker

TITLE
Independent Director
COMPENSATION
$80K
AGE
57
TENURE
2.8 yrs

Abe Hong

TITLE
Independent Director
COMPENSATION
$54K
AGE
47
TENURE
1.8 yrs

Glenn Krevlin

TITLE
Director
AGE
59
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • Joint individual insiders have sold more shares than they have bought in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
25. Mar 20 Buy Bandera Partners LLC Company 23. Mar 20 23. Mar 20 1,357 $8.46 $11,479
20. Mar 20 Buy Bandera Partners LLC Company 18. Mar 20 20. Mar 20 31,701 $8.49 $256,956
19. Mar 20 Sell Ronald DaVella Individual 18. Mar 20 18. Mar 20 -5,600 $8.43 $-45,724
17. Mar 20 Buy Bandera Partners LLC Company 13. Mar 20 17. Mar 20 122,687 $13.12 $1,389,317
17. Mar 20 Buy Peter Holt Individual 17. Mar 20 17. Mar 20 3,100 $9.47 $29,352
12. Mar 20 Buy Bandera Partners LLC Company 10. Mar 20 12. Mar 20 137,996 $13.49 $1,825,592
10. Mar 20 Buy Jake Singleton Individual 10. Mar 20 10. Mar 20 1,851 $13.50 $24,989
15. Nov 19 Sell Glenn Krevlin Individual 13. Nov 19 13. Nov 19 -100,000 $17.76 $-1,775,720
07. Jun 19 Buy James Amos Individual 05. Jun 19 05. Jun 19 4,000 $16.08 $64,325
24. May 19 Sell Ronald DaVella Individual 22. May 19 24. May 19 -10,190 $17.31 $-167,691
X
Management checks
We assess Joint's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Joint has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Can The Joint Corp.'s (NASDAQ:JYNT) ROE Continue To Surpass The Industry Average?

The formula for return on equity is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Joint: 64% = US$1.8m ÷ US$2.7m (Based on the trailing twelve months to June 2019.) Most readers would understand what net profit is, but it’s worth explaining the concept of shareholders’ equity. … Joint's Debt And Its 64% ROE While Joint does have some debt, with debt to equity of just 0.37, we wouldn't say debt is excessive. … A company that can achieve a high return on equity without debt could be considered a high quality business.

Simply Wall St -

Is The Joint Corp. (NASDAQ:JYNT) Trading At A 21% Discount?

We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. … A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value: 10-year free cash flow (FCF) estimate 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 Levered FCF ($, Millions) $6.3m $8.1m $10.7m $12.8m $14.7m $16.3m $17.7m $18.9m $20.0m $20.9m Growth Rate Estimate Source Analyst x2 Analyst x1 Analyst x1 Est @ 19.81% Est @ 14.68% Est @ 11.1% Est @ 8.59% Est @ 6.83% Est @ 5.6% Est @ 4.74% Present Value ($, Millions) Discounted @ 7.5% $5.9 $7.0 $8.6 $9.6 $10.2 $10.6 $10.7 $10.6 $10.4 $10.1 ("Est" = FCF growth rate estimated by Simply Wall St) Present Value of 10-year Cash Flow (PVCF)= $93.7m The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. … Terminal Value (TV) = FCF2029 × (1 + g) ÷ (r – g) = US$21m × (1 + 2.7%) ÷ (7.5% – 2.7%) = US$450m Present Value of Terminal Value (PVTV) = TV / (1 + r)10 = $US$450m ÷ ( 1 + 7.5%)10 = $218.50m The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is $312.15m.

Simply Wall St -

At US$17.68, Is It Time To Put The Joint Corp. (NASDAQ:JYNT) On Your Watch List?

(NASDAQ:JYNT), which is in the healthcare business, and is based in United States,. … As a stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock? … Let’s take a look at Joint’s outlook and value based on the most recent financial data to see if the opportunity still exists.

Simply Wall St -

The Joint Corp. (NASDAQ:JYNT) Delivered A Weaker ROE Than Its Industry

Our data shows Joint has a return on equity of 11% for the last year. … One way to conceptualize this, is that for each $1 of shareholders' equity it has, the company made $0.11 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Should You Worry About The Joint Corp.'s (NASDAQ:JYNT) CEO Pay Cheque?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Peter Holt's Compensation Compare With Similar Sized Companies. … is worth US$215m, and total annual CEO compensation is US$445k.

Simply Wall St -

Shareholders Should Look Hard At The Joint Corp.’s (NASDAQ:JYNT) 5.4% Return On Capital

Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … What is Return On Capital Employed (ROCE)? … ROCE measures the amount of pre-tax profits a company can generate from the capital employed in its business.

Simply Wall St -

Could The The Joint Corp. (NASDAQ:JYNT) Ownership Structure Tell Us Something Useful?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Companies that used to be publicly owned tend to have lower insider ownership. … With a market capitalization of US$149m, Joint is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

The Joint Corp. (NASDAQ:JYNT) Is Trading At A 47.31% Discount

Today, I will calculate the stock's intrinsic value. … by projecting its future cash flows and then discounting them to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

What You Must Know About The Joint Corp.'s (NASDAQ:JYNT) Financial Strength

Investors are always looking for growth in small-cap stocks like The Joint Corp. … However, an important fact which most ignore is: how financially healthy is the business? … Evaluating financial health as part of your investment thesis is

Simply Wall St -

Have Insiders Been Selling The Joint Corp. (NASDAQ:JYNT) Shares This Year?

But logic dictates you should pay some attention to whether insiders are buying or selling shares. … We generally tread carefully if insiders have been selling on market, even if they sold slightly above the current price. … Over the last year we saw more insider selling of Joint shares, than buying

Simply Wall St -

Company Info

Description

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising and the sale of regional developer rights. As of December 31, 2019, the company operated approximately 513 clinics in the United States. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.

Details
Name: The Joint Corp.
JYNT
Exchange: NasdaqCM
Founded: 2010
$141,189,418
13,882,932
Website: http://www.thejoint.com
Address: The Joint Corp.
16767 North Perimeter Drive,
Suite 240,
Scottsdale,
Arizona, 85260,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM JYNT Common Stock Nasdaq Capital Market US USD 11. Nov 2014
DB 1JO Common Stock Deutsche Boerse AG DE EUR 11. Nov 2014
Number of employees
Current staff
Staff numbers
150
Joint employees.
Industry
Health Care Facilities
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 03:14
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/06
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.